ClinicalTrials.gg
RecruitingNCT05794061NeuroPsiDUpdated Sep 17, 2025

Advances in Neuropsychological Diagnostics

An observational study in Cognitive Impairment, Dementia and Psychiatric Disorder, sponsored by Istituto Auxologico Italiano. Recruiting at 1 site in Italy. Open to participants aged 20 Years to 100 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2025-09-17.

Sponsored by Istituto Auxologico Italiano · Observational

How we know

From the registry’s dates

  • Started Nov 2021; still recruiting 5 years later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
300
Ages
20 Years to 100 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 175 studies in Cognitive Dysfunction with a site in Italy — 74 open to participants now, 87 under way, 6 of them phase 3. Cognitive Dysfunction · Italy.

Planned enrollment
20th of 64
300 · median 182
Started
2021
with 15 others
Observational
64 of 175
26 open now
Primary completion
2026-12
later than 46 of 86 live
Registered
71st of 175
by date
Lead sponsor
6 of 175
Istituto Auxologico Italiano

Among the 175 studies in Cognitive Dysfunction with a site in Italy, this one is the 20th largest by planned enrollment of the 64 observational ones that give a count, is one of 16 that started in 2021, is one of 64 observational ones, reaches primary completion later than 46 of the 86 other live ones, and was the 71st registered.

Cognitive Dysfunction

3,885 studies on the registry are indexed under Cognitive Dysfunction; 1,123 are open to participants now.

Browse Cognitive Dysfunction studies →

Open to participants now

74 of the 175 studies in Cognitive Dysfunction with a site in Italy are open now. Recruiting first, the newest first:

69 more — sign in →

All 74 open studies →

A study can be open while its sites in Italy have not opened yet or have stopped. Only those recruiting at a site in Italy →

Who these studies take

Of the 751 Cognitive Dysfunction studies recruiting now, 361 (48%) set no upper age limit and 144 (19%) stop at 75 or younger; 46 take children under 18; 260 take healthy volunteers.

This study: 20 Years to 100 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 175 studies in Cognitive Dysfunction with a site in Italy, or all of them as a file.
02

Study summary

This project is aimed at advancing neuropsychological diagnostics, enriching and modernizing the panorama of both clinical and forensic psychometric testing. The rapid socio-demographic changes, the developments of neuropsychological semiotics and nosography, as well as the growing applicative specialization of neuropsychological assessment make it necessary to introduce further tools to satisfy the diagnostic requests in clinical contexts and more recently in the forensic field (i.e., tests to be administered remotely; bedside screeners; domain-specific in-depth tests; tools for assessing testamentary capacity).

Specifically, the present study aims to: a) develop, calibrate and evaluate the psychometric properties of I and II level clinical and/or forensic neuropsychological tests evaluating instrumental and non-instrumental functions in a sample of neurologically healthy individuals representative of the Italian population ; b) evaluate the cross-sectional and longitudinal clinical usability of the aforementioned tests in clinical samples (patients with neurological and neuropsychiatric pathologies of different etiology).

03

Conditions studied

  • Cognitive Impairment
  • Dementia
  • Psychiatric Disorder
04

Who can participate

Ages eligible
20 Years to 100 Years
Sexes eligible
All
Accepts healthy volunteers
Yes
Sampling method
Non-probability sample

Study population

Individuals with brain disorders and normotypical.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Clinical populations: clinical diagnosis of either neurological (e.g., vascular and degenerative aetiologies) or psychiatric disorders.
  • Healthy controls: not applicable

Exclusion criteria

Exclusion Criteria:

  • Clinical populations:

    1. Clinical diagnosis not of interest;
    2. Severe general medical conditions;
    3. Uncorrected vision/hearing deficits.
  • Healthy controls:

    1. Presence of brain disorders;
    2. Severe general medical conditions;
    3. Uncorrected vision/hearing deficits.
05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
300 participants (estimated)
Patient registry
No

Groups and cohorts

  • Patients

    Patients with brain disorders

    Behavioral: Neuropsychological instruments

  • Healthy controls

    Neurologically Healthy Controls

    Behavioral: Neuropsychological instruments

Interventions

  • BehavioralNeuropsychological instruments

    Cognitive and behavioral tests and questionnaires

06

What researchers measure

Primary outcomes

  1. Change from baseline in Brief Assessment of Social Skills-Dementia (BASS-D)

    A screening test of social cognition in neurodegeneration

    Time frame: At baseline (i.e., at the enrollment; all participants); after 1 month (for test-retest analyses in neurologically healthy individuals); after 6, 12, and 18 months in participants with neurodegenerative disorders

  2. Change from baseline in Picture Interpretation Test (PIT)

    A test of executive functions

    Time frame: At baseline (i.e., at the enrollment; all participants); after 1 month (for test-retest analyses in neurologically healthy individuals); after 6, 12, and 18 months in participants with neurodegenerative disorders

  3. Change from baseline in Verbal Reasoning Test (VRT-A) - Absurdity sub-test

    A test of verbal reasoning

    Time frame: At baseline (i.e., at the enrollment; all participants); after 1 month (for test-retest analyses in neurologically healthy individuals); after 6, 12, and 18 months in participants with neurodegenerative disorders

  4. Change from baseline in Brief Executive Language Screen (BELS)

    A language test

    Time frame: At baseline (i.e., at the enrollment; all participants); after 1 month (for test-retest analyses in neurologically healthy individuals); after 6, 12, and 18 months in participants with neurodegenerative disorders

  5. Change from baseline in Bamberg Dementia Screening Test (BDST)

    A test of global cognitive efficiency

    Time frame: At baseline (i.e., at the enrollment; all participants); after 1 month (for test-retest analyses in neurologically healthy individuals); after 6, 12, and 18 months in participants with neurodegenerative disorders

  6. Change from baseline in Testament Definition Scale (TDS)

    A scale to assess testament representation

    Time frame: At baseline (i.e., at the enrollment; all participants); after 1 month (for test-retest analyses in neurologically healthy individuals); after 6, 12, and 18 months in participants with neurodegenerative disorders

  7. Change from baseline in Testamentary Capacity Assessment Tool (TCAT)

    A test to assess cognitive functions (i.e., memory, executive functions, social cognition, and numerical abilities) at the base of testamentary capacity

    Time frame: At baseline (i.e., at the enrollment; all participants); after 1 month (for test-retest analyses in neurologically healthy individuals); after 6, 12, and 18 months in participants with neurodegenerative disorders

  8. Change from baseline in Telephone Interview for Cognitive Status (TICS)

    A telephone-based screening test of global cognitive efficiency

    Time frame: At baseline (i.e., at the enrollment; all participants); after 1 month (for test-retest analyses in neurologically healthy individuals); after 6, 12, and 18 months in participants with neurodegenerative disorders

  9. Change from baseline in Telephone-based Mini-Mental State Examination (I-TEL-MMSE)

    A telephone-based screening test of global cognitive efficiency

    Time frame: At baseline (i.e., at the enrollment; all participants); after 1 month (for test-retest analyses in neurologically healthy individuals); after 6, 12, and 18 months in participants with neurodegenerative disorders

  10. Change from baseline in Telephone-based Global Examination of Mental State (tele-GEMS)

    A telephone-based screening test of global cognitive efficiency

    Time frame: At baseline (i.e., at the enrollment; all participants); after 1 month (for test-retest analyses in neurologically healthy individuals); after 6, 12, and 18 months in participants with neurodegenerative disorders

  11. Change from baseline in Telephone-based Amyotrophic Lateral Sclerosis Cognitive Behavioural Screen (ALS-CBS™-PhV

    A telephone-based screening test for cognitive functions in ALS

    Time frame: At baseline (i.e., at the enrollment; all participants); after 1 month (for test-retest analyses in neurologically healthy individuals); after 6, 12, and 18 months in participants with neurodegenerative disorders

  12. Change from baseline in Telephone-based Frontal Assessment Battery (t-FAB)

    A telephone-based screening test of executive functions

    Time frame: At baseline (i.e., at the enrollment; all participants); after 1 month (for test-retest analyses in neurologically healthy individuals); after 6, 12, and 18 months in participants with neurodegenerative disorders

  13. Change from baseline in Development of the Bizzare Pictures Test (BPT)

    A new visual test to assess reasoning abilities

    Time frame: At baseline (i.e., at the enrollment; all participants); after 1 month (for test-retest analyses in neurologically healthy individuals); after 6, 12, and 18 months in participants with neurodegenerative disorders

  14. Change from baseline in Development Telephone Language Screener (TLS)

    A new telephone-based test to asses linguistic functions

    Time frame: At baseline (i.e., at the enrollment; all participants); after 1 month (for test-retest analyses in neurologically healthy individuals); after 6, 12, and 18 months in participants with neurodegenerative disorders

07

Study locations

1 of 1 sites recruiting
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Nov 2021 (actual). Primary completion is estimated for Dec 2026, 61 months after the start.

Of 506 non-industry observational studies under Cognitive Dysfunction, half reached primary completion within 49 months of starting (the median), counting those still running; a quarter within 22 and three quarters within 118. This study's planned 61 months is above that.

Counting every sponsor, half of 545 studies reached it within 48 months; a quarter within 21 and three quarters within 118.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 24, 2023
First posted
Mar 31, 2023
StartActual
Nov 11, 2021
Primary completionEst.
Dec 31, 2026
CompletionEst.
Dec 31, 2026
Last update
Sep 17, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 17, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT05794061
Responsible party
Sponsor
First posted
Mar 31, 2023
Start date
Nov 11, 2021
Primary completion
Dec 31, 2026 (estimated)
Completion
Dec 31, 2026 (estimated)
Last update
Sep 17, 2025

Study contacts

Nadia Bolognini, PhD
Contact
n.bolognini@auxologico.it
+390261911 ext. 6127

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion